Drug Trial News

RSS

New national program targeting harmful and unnecessary medicine use in Australia

...

1 Jul 2026

Trial evaluates interdisciplinary care for veterans with brain trauma and PTSD

The Medical College of Wisconsin (MCW) is leading a new multi-center clinical trial to evaluate an interdisciplinary rehabilitation model for military veterans and first responders with mild traumatic brain injury (mTBI) and co-occurring disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD).

30 Jun 2026

New trial shows oral therapy increases growth in children with achondroplasia

New findings from a trial conducted at Children's Hospital Colorado (Children's Colorado) and University of Colorado (CU) Anschutz School of Medicine demonstrate significantly increased growth rates in children with achondroplasia, the most common form of dwarfism.

30 Jun 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

Common drug shows promise in preventing post-surgical liver failure

A multi-center study, co-led by researchers at Mayo Clinic and Michigan State University, found that patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than patients who received a placebo.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

New oral drug shows promise for chronic heart failure treatment

An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart failure.

24 Jun 2026

UCI Health launches world's first embryonic stem cell trial for Huntington's disease

UCI Health, the clinical enterprise of the University of California, Irvine, has opened the world's first in-human embryonic stem cell-derived clinical trial for Huntington's disease.

23 Jun 2026

New drug could double survival time in patients with advanced pancreatic cancer

A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical trial results presented at the American Society of Clinical Oncology (ASCO) 2026 annual meeting and simultaneously published in The New England Journal of Medicine.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

First human trial targets aging immune cells for healthier immunity

A first-in-human clinical trial of an immune rejuvenation therapy designed to restore the function of worn-out T cells is expected to begin later this year, building on research led by UCL scientists into the mechanisms of immune aging.

17 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Novel gene therapy appears to be safe for Friedreich ataxia cardiomyopathy

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.

17 Jun 2026

Tirzepatide activates calorie-burning brown fat to combat obesity

Tirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

New USC clinical trial explores psilocybin for mental health

Researchers at the Keck School of Medicine of USC, the Brain and Creativity Institute at the USC Dornsife College of Letters, Arts and Sciences, and the USC Norris Comprehensive Cancer Center have launched the University of Southern California's first study of psychedelic therapy.

16 Jun 2026

Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.

13 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026

Study supports atropine drops for managing childhood short-sightedness

Low concentration atropine eye drops are a safe and effective treatment for short-sightedness (myopia) in UK children, although the effects are small, suggests a clinical trial published by The BMJ today.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026